Contact
searchSearch
HMP Global
Login
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology
Kathleen Moore, MD
Videos
Trastuzumab Pamirtecan Produces Durable Responses Across HER2 Expression Levels in Advanced Endometrial Cancer
06/17/2026
Kathleen Moore, MD
Kathleen Moore, MD, discusses updated phase 1/2 data showing that trastuzumab pamirtecan achieved durable responses and encouraging survival outcomes across HER2-expressing subgroups of advanced endometrial cancer, with the greatest activity...
Kathleen Moore, MD, discusses updated phase 1/2 data showing that trastuzumab pamirtecan achieved durable responses and encouraging survival outcomes across HER2-expressing subgroups of advanced endometrial cancer, with the greatest activity...
Kathleen Moore, MD, discusses...
06/17/2026
Oncology
News
Mocertatug Rezetecan Demonstrates Encouraging Activity in Platinum-Resistant Ovarian and Endometrial Cancer
06/17/2026
Stephanie Holland
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1 BEHOLD-1 trial demonstrated that mocertatug rezetecan showed encouraging antitumor activity among patients with platinum-resistant ovarian cancer and advanced or recurrent endometrial cancer.
Results from the phase 1...
06/17/2026
Oncology
Mansoor Raza Mirza, MD, Copenhagen University Hospital, Denmark
Conference Coverage
Beyond Immunotherapy Treatment for Patients With Recurrent Metastatic Endometrial Cancer
02/24/2023
At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.
At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.
At the 2023 ESMO Gynecological...
02/24/2023
Oncology
Conference Coverage
Impact of BRCA Mutation Location on PARP Inhibitor Efficacy for Patients with Advanced Ovarian Cancer
02/23/2023
According to study results presented at the 2023 ESMO Gynecological Cancers Congress, the location and type of BRCA mutation may impact the effectiveness of PARP inhibitor treatment for patients with advanced ovarian cancer.
According to study results presented at the 2023 ESMO Gynecological Cancers Congress, the location and type of BRCA mutation may impact the effectiveness of PARP inhibitor treatment for patients with advanced ovarian cancer.
According to study results...
02/23/2023
Oncology
Conference Coverage
Optimal Treatment Modality for Patients With Advanced Cervical Cancer
02/23/2023
Derek Cowsert
Data presented at the 2023 ESMO Gynecological Cancers Congress shows survival outcomes were improved among patients with late-stage cervical cancer who received adjuvant chemoradiotherapy compared with other treatment modalities.
Data presented at the 2023 ESMO Gynecological Cancers Congress shows survival outcomes were improved among patients with late-stage cervical cancer who received adjuvant chemoradiotherapy compared with other treatment modalities.
Data presented at the 2023 ESMO...
02/23/2023
Oncology
Conference Coverage
Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
02/23/2023
Derek Cowsert
According to study results presented at the 2023 ESMO Gynecological Cancers Congress, patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin experienced clinically meaningful and durable anti-tumor activity.
According to study results presented at the 2023 ESMO Gynecological Cancers Congress, patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin experienced clinically meaningful and durable anti-tumor activity.
According to study results...
02/23/2023
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use